+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Vaccines Market by Technology (Live, Toxoid, Recombinant), Disease (Pneumococcal, Influenza, DTP, Rotavirus, TT, Polio, MMR, Varicella, Dengue, TB, shingles, Rabies), Route (IM, SC, ID, Oral), Patient (Pediatric, Adult), Type - Global Forecast to 2024

  • ID: 4969181
  • Report
  • January 2020
  • Region: Global
  • 189 Pages
  • Markets and Markets
1 of 6
The Vaccines Market is Projected to Grow at a CAGR of 7.0% During the Forecast Period (2019–2024)

FEATURED COMPANIES

  • and Merck & Co. Inc.
  • Bavarian Nordic
  • Bio Farma
  • CSL Limited
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • MORE

The global vaccines market is projected to reach USD 58.4 billion by 2024 from USD 41.7 billion in 2019, at a CAGR of 7.0% during the forecast period. The key factors driving the growth of this market include the high prevalence of infectious diseases, growing support for vaccine R&D, investments in vaccine development, and rising focus on immunization. However, the huge capital investments required for developing vaccines may restrain market growth.

The pneumococcal disease segment will continue to dominate the vaccines market during the forecast period.

On the basis of disease indication, the vaccines market is segmented into pneumococcal disease, influenza, DTP, hepatitis, human papillomavirus (HPV), rotavirus, meningococcal disease, MMR (measles, mumps, and rubella), varicella, polio, herpes zoster, and other disease indications. The pneumococcal disease segment accounted for the largest share of the vaccines market in 2018. The large share of this segment can be attributed to the high incidence of pneumococcal disease and increasing government investments in pneumococcal vaccination programs.

By type, the monovalent vaccines segment accounted for the larger share of the vaccines market in 2019.

On the basis of type, the vaccines market is segmented into monovalent and multivalent vaccines. The monovalent vaccines segment accounted for the largest share of the vaccines market in 2018. The large share of this segment can be attributed to the rising prevalence of diseases and increasing government & non-government initiatives to promote immunization.

The market in Asia is projected to witness the highest growth rate during the forecast period (2019–2024).

Asia is projected to register the highest growth during the forecast period. Growing company investments in Asian countries and rising government support for vaccine development are some of the key factors supporting the growth of the vaccines market in Asia.

A breakdown of the primary participants referred to for this report is provided below:

  • By Company Type: Tier 1: 47%, Tier 2: 26%, and Tier 3: 27%
  • By Designation: C-level: 33%, Director-level: 21%, and Others: 46%
  • By Region: North America: 36%, Europe: 31%, Asia: 16%, and the RoW: 17%

GlaxoSmithKline plc (UK), Pfizer, Inc. (US), Sanofi Pasteur (France), and Merck & Co., Inc. (US) are the leading players in the global vaccines market. Other notable players in this market include CSL Limited (Australia), Emergent BioSolutions, Inc. (US), Johnson & Johnson (US), AstraZeneca (UK), Serum Institute of India Pvt. Ltd. (India), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan), Daiichi Sankyo (Japan), Panacea Biotec (India), Biological E (India), Bharat Biotech (India), Sinovac Biotech Ltd (China), Incepta Vaccine LTD. (Bangladesh), Valneva SE (France), VBI Vaccines Inc. (US), and Bio Farma (Brazil).

Research Coverage:
The report analyzes the vaccines market and aims at estimating the market size and future growth potential of this market based on various segments such as technology, type, disease indication, route of administration, patient type, and region. The report also includes competitive analysis of the key players in this market along with their company profiles, product and service offerings, recent developments, and key market strategies.

Reasons to Buy the Report
The report can help established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one, or a combination of the below mentioned five strategies.

This report provides insights into the following pointers:

  • Market Penetration: Comprehensive information on the product portfolios of the top players in the vaccines market. The report analyzes the market based on technology, type, disease indication, route of administration, patient type, and region.
  • Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in the vaccines market.
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of vaccines across regions.
  • Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the vaccines market.
  • Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the vaccines market.
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • and Merck & Co. Inc.
  • Bavarian Nordic
  • Bio Farma
  • CSL Limited
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • MORE

1 Introduction
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Market Covered
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders

2 Research Methodology  
2.1 Research Approach
2.1.1 Secondary Research
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Research
2.1.2.1 Key Data From Primary Sources
2.1.2.2 Breakdown of Primaries
2.2 Market Size Estimation
2.3 Data Triangulation Approach
2.4 Market Share Analysis
2.5 Assumptions for the Study

3 Executive Summary

4 Premium Insights
4.1 Vaccines Market Overview
4.2 North America: Vaccines Market, By Technology (2018)
4.3 Geographical Snapshot of the Vaccines Market

5 Market Overview
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 High Prevalence of Infectious Diseases
5.2.1.2 Rising Focus on Immunization Programs
5.2.1.3 Growing Government Support for Vaccine Development
5.2.1.4 Increasing Company Initiatives to Enhance Vaccine R&D
5.2.2 Restraints
5.2.2.1 High Cost of Vaccine Development
5.2.3 Opportunities
5.2.3.1 High Growth Prospects in Emerging Markets
5.2.3.2 Focus on Therapeutic Vaccines
5.2.3.3 Use of Adjuvants in Vaccines
5.2.4 Challenges
5.2.4.1 Inadequate Access to Vaccines
5.2.5 Burning Issues
5.2.5.1 Product Recalls

6 Industry Insights
6.1 Regulatory Landscape
6.1.1 North America
6.1.2 Europe
6.1.3 Asia
6.1.4 RoW
6.2 Key Pipeline Products
6.3 New Vaccine Opportunities
6.3.1 HIV
6.3.1.1 HIV Vaccine: Product Pipeline
6.3.1.2 HIV Vaccine: Public-Private Initiatives
6.3.1.3 HIV Vaccine: Funding
6.3.2 Malaria
6.3.2.1 Malaria Vaccine: Product Pipeline
6.3.2.2 Malaria Vaccine: Public-Private Initiatives
6.3.3 Zika
6.3.3.1 Zika Vaccine: Product Pipeline
6.3.3.2 Zika Vaccine: Public-Private Initiatives
6.3.3.3 Zika Vaccine: Funding
6.3.4 Ebola
6.3.4.1 Ebola Vaccine: Product Pipeline
6.3.4.2 Ebola Vaccine: Public-Private Initiatives
6.3.4.3 Ebola Vaccine: Funding

7 Vaccines Market, By Technology
7.1 Introduction
7.2 Conjugate Vaccines
7.2.1 Conjugate Vaccines Hold the Largest Share of the Market
7.3 Inactivated & Subunit Vaccines
7.3.1 Ease of Storage and Transportation have Made Inactivated & Subunit Vaccines Popular
7.4 Live Attenuated Vaccines
7.4.1 Issues in Preserving and Maintaining Live Attenuated Vaccines has Slowed Market Growth
7.5 Recombinant Vaccines
7.5.1 Lack of Post-Vaccination Reactions and Reduced Need for Booster Doses are Driving R&D Into Recombinant Vaccines
7.6 Toxoid Vaccines
7.6.1 Company Initiatives and the Introduction of New Vaccines Will Support Market Growth

8 Vaccines Market, By Type  
8.1 Introduction
8.2 Monovalent Vaccines
8.2.1 in 2018, the Monovalent Vaccines Segment Accounted for the Largest Share of the Market
8.3 Multivalent Vaccines
8.3.1 Increasing Initiatives By Companies to Develop New Multivalent Vaccines is Driving the Growth of This Segment

9 Vaccines Market, By Disease Indication  
9.1 Introduction
9.2 Pneumococcal Disease
9.2.1 Pneumococcal Disease Segment Accounted for the Largest Share of the Market
9.3 DTP
9.3.1 Increasing Accessibility of DTP Vaccines in Developing Countries to Drive Market Growth
9.4 Influenza
9.4.1 Influenza Vaccines Segment to Grow at the Highest Rate During the Forecast Period
9.5 HPV
9.5.1 Growing Prevalence of HPV Infections to Support Market Growth
9.6 Meningococcal Disease
9.6.1 Rising Incidence of Meningococcal Disease to Support the Growth of This Market Segment
9.7 Polio
9.7.1 Government Initiatives to Support the Growth of This Market Segment
9.8 Hepatitis
9.8.1 High Prevalence of Hepatitis Infections is Driving the Demand for Immunization
9.9 Rotavirus
9.9.1 Rising Incidence of Rotavirus Infections to Drive Market Growth
9.10 MMR
9.10.1 Rising Incidence of Measles, Mumps, and Rubella Will Support the Growth of This Market Segment
9.11 Varicella
9.11.1 Promotion of Immunization Programs to Drive the Demand for Varicella Vaccines
9.12 Herpes Zoster
9.12.1 Herpes Zoster Vaccines to Witness Stable Demand During the Forecast Period
9.13 Other Disease Indications

10 Vaccines Market, By Route of Administration   
10.1 Introduction
10.2 Intramuscular and Subcutaneous Administration
10.2.1 Intramuscular and Subcutaneous Administration Accounted for the Largest Share of the Market
10.3 Oral Administration
10.3.1 Possibility of Irritation of the Gastric Mucosa May Limit the Growth of This Segment
10.4 Other Routes of Administration

11 Vaccines Market, By Patient Type
11.1 Introduction
11.2 Pediatric Patients
11.2.1 in 2018, the Pediatric Patients Segment Accounted for the Largest Share of the Market
11.3 Adult Patients
11.3.1 The Adult Patients Segment is Expected to Grow at the Highest CAGR During the Forecast Period

12 Vaccines Market, By Region  
12.1 Introduction
12.2 North America
12.2.1 US
12.2.1.1 The US is the Largest Market for Vaccines
12.2.2 Canada
12.2.2.1 High Incidence of Infectious Diseases is Driving the Demand for Vaccines in the Country
12.3 Europe
12.3.1 Germany
12.3.1.1 Significant Investments in R&D to Support Market Growth
12.3.2 UK
12.3.2.1 Launch of New Products to Support Market Growth in the UK in the Coming Years
12.3.3 France
12.3.3.1 Favorable Government Initiatives for Immunization to Support Market Growth in France
12.3.4 Italy
12.3.4.1 Conjugate Vaccines to Account for the Largest Share of the Italian Market
12.3.5 Spain
12.3.5.1 Rising Investments in Vaccine Development By Private Organizations to Support Market Growth in Spain
12.3.6 Rest of Europe
12.4 Asia
12.4.1 Japan
12.4.1.1 Government Initiatives for Increasing the Accessibility of Vaccines to Drive Market Growth in Japan
12.4.2 China
12.4.2.1 Growing Investments in the Biotechnology Sector to Drive Market Growth in China
12.4.3 India
12.4.3.1 Growth of the Biotechnology Sector and Development of New Vaccines to Support Market Growth in India
12.4.4 Rest of Asia
12.5 Rest of the World
12.5.1 Latin America
12.5.2 Other RoW Countries

13 Competitive Landscape
13.1 Overview
13.2 Market Share Analysis
13.3 Competitive Leadership Mapping (Overall Market)
13.3.1 Visionary Leaders
13.3.2 Innovators
13.3.3 Dynamic Differentiators
13.3.4 Emerging Companies
13.4 Competitive Situation and Trends
13.4.1 Agreements, Contracts, and Collaborations
13.4.2 Product Launches and Approvals
13.4.3 Acquisitions
13.4.4 Expansions

14 Company Profiles
14.1 Glaxosmithkline PLC
14.1.1 Business Overview
14.1.2 Products Offered
14.1.3 Recent Developments (2016–2019)
14.1.4 MnM View
14.2 Pfizer, Inc
14.2.1 Business Overview
14.2.2 Products Offered
14.2.3 Recent Developments (2016–2019)
14.2.4 MnM View
14.3 Merck & Co., Inc
14.3.1 Business Overview
14.3.2 Products Offered
14.3.3 Recent Developments (2016–2019)
14.3.4 MnM View
14.4 Sanofi Pasteur SA
14.4.1 Business Overview
14.4.2 Products Offered
14.4.3 Recent Developments (2016–2019)
14.4.4 MnM View
14.5 CSL Limited
14.5.1 Business Overview
14.5.2 Products Offered
14.5.3 Recent Developments (2016–2019)
14.6 Emergent Biosolutions, Inc
14.6.1 Business Overview
14.6.2 Products Offered
14.6.3 Recent Developments (2016–2019)
14.7 Johnson & Johnson
14.7.1 Business Overview
14.7.2 Products Offered
14.7.3 Recent Developments (2016–2019)
14.8 Astrazeneca
14.8.1 Business Overview
14.8.2 Products Offered
14.8.3 Recent Developments (2016–2019)
14.9 Serum Institute of India Pvt., LTD
14.9.1 Business Overview
14.9.2 Products Offered
14.9.3 Recent Developments (2016–2019)
14.10 Bavarian Nordic
14.10.1 Business Overview
14.10.2 Products Offered
14.10.3 Recent Developments (2016–2019)
14.11 Mitsubishi Tanabe Pharma Corporation
14.11.1 Business Overview
14.11.2 Products Offered
14.11.3 Recent Developments (2016–2019)
14.12 Daiichi Sankyo Company, Limited
14.12.1 Business Overview
14.12.2 Products Offered
14.12.3 Recent Developments (2016–2019)
14.13 Panacea Biotec, LTD
14.13.1 Business Overview
14.13.2 Products Offered
14.13.3 Recent Developments (2016–2019)
14.14 Biological E
14.14.1 Business Overview
14.14.2 Products Offered
14.14.3 Recent Developments (2016–2019)
14.15 Bharat Biotech
14.15.1 Business Overview
14.15.2 Products Offered
14.15.3 Recent Developments (2016–2019)
14.16 Other Companies
14.16.1 Sinovac Biotech, LTD
14.16.2 Incepta Vaccine, LTD
14.16.3 Valneva SE
14.16.4 Vbi Vaccines Inc
14.16.5 Pt Bio Farma (Persero)

15 Appendix
15.1 Discussion Guide
15.2 Knowledge Store
15.3 Available Customizations
15.4 Related Reports
15.5 Author Details

List of Tables (108 Tables)
Table 1 Incidence of Infectious Diseases
Table 2 Nih Funding for Vaccine Research, 2013–2018 (USD Million)
Table 3 Immunization Coverage, By Disease, 2016 vs 2018
Table 4 Regulatory Authorities in Europe
Table 5 Regulatory Authorities in Asia
Table 6 Key Pipeline Vaccines
Table 7 Ebola Projects Funded By EC (2014–2020)
Table 8 Vaccines Market, By Technology, 2017–2024 (USD Million)
Table 9 Cost of Meningococcal Conjugate Vaccines for Pediatric Patients
Table 10 Cost of Meningococcal Conjugate Vaccines for Adult Patients
Table 11 Conjugate Vaccines Market, By Region, 2017–2024 (USD Million)
Table 12 Examples of Inactivated & Subunit Vaccines
Table 13 Inactivated & Subunit Vaccines Market, By Region, 2017–2024 (USD Million)
Table 14 Live Attenuated Vaccines Market, By Region, 2017–2024 (USD Million)
Table 15 Examples of Recombinant Vaccines
Table 16 Recombinant Vaccines Market, By Region, 2017–2024 (USD Million)
Table 17 Toxoid Vaccines Market, By Region, 2017–2024 (USD Million)
Table 18 Vaccines Market, By Type, 2017–2024 (USD Million)
Table 19 Monovalent Vaccines Market, By Region, 2017–2024 (USD Million)
Table 20 Examples of Notable Multivalent Vaccines Available in the Market
Table 21 Multivalent Vaccines Market, By Region, 2017–2024 (USD Million)
Table 22 Vaccines Market, By Disease Indication, 2017–2024 (USD Million)
Table 23 List of Commercially Available Pneumococcal Vaccines in the Market
Table 24 Vaccines Market for Pneumococcal Disease, By Region, 2017–2024 (USD Million)
Table 25 List of Commercially Available DTP Vaccines in the Market
Table 26 Vaccines Market for DTP, By Region, 2017–2024 (USD Million)
Table 27 List of Commercially Available Influenza Vaccines in the Market
Table 28 Vaccines Market for Influenza, By Region, 2017–2024 (USD Million)
Table 29 List of Commercially Available HPV Vaccines in the Market
Table 30 Vaccines Market for HPV, By Region, 2017–2024 (USD Million)
Table 31 List of Commercially Available Meningococcal Disease Vaccines in the Market
Table 32 Vaccines Market for Meningococcal Disease, By Region, 2017–2024 (USD Million)
Table 33 List of Commercially Available Polio Vaccines in the Market
Table 34 Vaccines Market for Polio, By Region, 2017–2024 (USD Million)
Table 35 List of Commercially Available Hepatitis Vaccines in the Market
Table 36 Vaccines Market for Hepatitis, By Region, 2017–2024 (USD Million)
Table 37 List of Commercially Available Rotavirus Vaccines in the Market
Table 38 Vaccines Market for Rotavirus, By Region, 2017–2024 (USD Million)
Table 39 List of Commercially Available MMR Vaccines in the Market
Table 40 Vaccines Market for MMR, By Region, 2017–2024 (USD Million)
Table 41 List of Commercially Available Varicella Vaccines in the Market
Table 42 Vaccines Market for Varicella, By Region, 2017–2024 (USD Million)
Table 43 Vaccines Market for Herpes Zoster, By Region, 2017–2024 (USD Million)
Table 44 List of Commercially Available Vaccines for Other Disease Indications
Table 45 Vaccines Market for Other Disease Indications, By Region, 2017–2024 (USD Million)
Table 46 Vaccines Market, By Route of Administration, 2017–2024 (USD Million)
Table 47 Advantages and Disadvantages of Intramuscular and Subcutaneous Administration
Table 48 Vaccines Market for Intramuscular and Subcutaneous Administration, By Region, 2017–2024 (USD Million)
Table 49 Vaccines Market for Oral Administration, By Region, 2017–2024 (USD Million)
Table 50 Vaccines Market for Other Routes of Administration, By Region, 2017–2024 (USD Million)
Table 51 Vaccines Market, By Patient Type, 2017–2024 (USD Million)
Table 52 Vaccines Market for Pediatric Patients, By Region, 2017–2024 (USD Million)
Table 53 North America: Vaccines Market for Pediatric Patients, By Country, 2017–2024 (USD Million)
Table 54 Vaccines Market for Adult Patients, By Region, 2017–2024 (USD Million)
Table 55 North America: Vaccines Market for Adult Patients, By Country, 2017–2024 (USD Million)
Table 56 Vaccines Market, By Region, 2017–2024 (USD Million)
Table 57 North America: Vaccines Market, By Country, 2017–2024 (USD Million)
Table 58 North America: Vaccines Market, By Technology, 2017–2024 (USD Million)
Table 59 North America: Vaccines Market, By Type, 2017–2024 (USD Million)
Table 60 North America: Vaccines Market, By Disease Indication, 2017–2024 (USD Million)
Table 61 North America: Vaccines Market, By Route of Administration, 2017–2024 (USD Million)
Table 62 North America: Vaccines Market, By Patient Type, 2017–2024 (USD Million)
Table 63 Number of New Infectious Disease Cases in the Us, 2017
Table 64 US: Vaccines Market, By Technology, 2017–2024 (USD Million)
Table 65 US: Vaccines Market, By Patient Type, 2017–2024 (USD Million)
Table 66 Number of New Infectious Disease Cases in Canada
Table 67 Canada: Vaccines Market, By Technology, 2017–2024 (USD Million)
Table 68 Canada: Vaccines Market, By Patient Type, 2017–2024 (USD Million)
Table 69 Europe: Vaccines Market, By Country, 2017–2024 (USD Million)
Table 70 Europe: Vaccines Market, By Technology, 2017–2024 (USD Million)
Table 71 Europe: Vaccines Market, By Type, 2017–2024 (USD Million)
Table 72 Europe: Vaccines Market, By Disease Indication, 2017–2024 (USD Million)
Table 73 Europe: Vaccines Market, By Route of Administration, 2017–2024 (USD Million)
Table 74 Europe: Vaccines Market, By Patient Type, 2017–2024 (USD Million)
Table 75 Germany: Vaccines Market, By Technology, 2017–2024 (USD Million)
Table 76 UK: Vaccines Market, By Technology, 2017–2024 (USD Million)
Table 77 France: Vaccines Market, By Technology, 2017–2024 (USD Million)
Table 78 Italy: Vaccines Market, By Technology, 2017–2024 (USD Million)
Table 79 Spain: Vaccines Market, By Technology, 2017–2024 (USD Million)
Table 80 RoE: Vaccines Market, By Technology, 2017–2024 (USD Million)
Table 81 Asia: Health Expenditure Per Capita, By Country, 2000, 2014, and 2016 (USD)
Table 82 Asia: Vaccines Market, By Country, 2017–2024 (USD Million)
Table 83 Asia: Vaccines Market, By Technology, 2017–2024 (USD Million)
Table 84 Asia: Vaccines Market, By Type, 2017–2024 (USD Million)
Table 85 Asia: Vaccines Market, By Disease Indication, 2017–2024 (USD Million)
Table 86 Asia: Vaccines Market, By Route of Administration, 2017–2024 (USD Million)
Table 87 Asia: Vaccines Market, By Patient Type, 2017–2024 (USD Million)
Table 88 Disease Incidence in Japan, 2016–2018
Table 89 Japan: Vaccines Market, By Technology, 2017–2024 (USD Million)
Table 90 China: Vaccines Market, By Technology, 2017–2024 (USD Million)
Table 91 India: Vaccines Market, By Technology, 2017–2024 (USD Million)
Table 92 RoA: Vaccines Market, By Technology, 2017–2024 (USD Million)
Table 93 RoW: Vaccines Market, By Region, 2017–2024 (USD Million)
Table 94 RoW: Vaccines Market, By Technology, 2017–2024 (USD Million)
Table 95 RoW: Vaccines Market, By Type, 2017–2024 (USD Million)
Table 96 RoW: Vaccines Market, By Disease Indication, 2017–2024 (USD Million)
Table 97 RoW: Vaccines Market, By Route of Administration, 2017–2024 (USD Million)
Table 98 RoW: Vaccines Market, By Patient Type, 2017–2024 (USD Million)
Table 99 Latin America: Vaccines Market, By Technology, 2017–2024 (USD Million)
Table 100 Latin America: Vaccines Market, By Type, 2017–2024 (USD Million)
Table 101 Latin America: Vaccines Market, By Disease Indication, 2017–2024 (USD Million)
Table 102 Latin America: Vaccines Market, By Route of Administration, 2017–2024 (USD Million)
Table 103 Latin America: Vaccines Market, By Patient Type, 2017–2024 (USD Million)
Table 104 Other RoW Countries: Vaccines Market, By Technology, 2017–2024 (USD Million)
Table 105 Other RoW Countries: Vaccines Market, By Type, 2017–2024 (USD Million)
Table 106 Other RoW Countries: Vaccines Market, By Disease Indication, 2017–2024 (USD Million)
Table 107 Other RoW Countries: Vaccines Market, By Route of Administration, 2017–2024 (USD Million)
Table 108 Other RoW Countries: Vaccines Market, By Patient Type, 2017–2024 (USD Million)

List of Figures (35 Figures)
Figure 1 Vaccines Market Segmentation
Figure 2 Research Design
Figure 3 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 4 Bottom-Up Approach
Figure 5 Top-Down Approach
Figure 6 Data Triangulation Methodology
Figure 7 Vaccines Market, By Technology, 2019 vs 2024 (USD Million)
Figure 8 Vaccines Market, By Type, 2019 vs 2024 (USD Million)
Figure 9 Vaccines Market, By Disease Indication, 2019 vs 2024 (USD Million)
Figure 10 Vaccines Market, By Route of Administration, 2019 vs 2024 (USD Million)
Figure 11 Vaccines Market, By Patient Type, 2019 vs 2024 (USD Million)
Figure 12 Geographical Snapshot of the Vaccines Market
Figure 13 High Prevalence of Diseases and Rising Focus on Immunization Programs are Driving Market Growth
Figure 14 Conjugate Vaccines Accounted for the Largest Share of the North American Vaccines Market in 2018
Figure 15 Asia to Witness the Highest Growth in the Vaccines Market From 2019 to 2024
Figure 16 Vaccines Market: Drivers, Restraints, Opportunities, and Challenges
Figure 17 Regulatory Approval Process for Vaccines
Figure 18 North America Will Continue to Dominate the Vaccines Market in 2024
Figure 19 North America: Vaccines Market Snapshot
Figure 20 Europe: Vaccines Market Snapshot
Figure 21 Asia: Vaccines Market Snapshot
Figure 22 Vaccines Market Share Analysis, By Key Player, 2018 127
Figure 23 Competitive Leadership Mapping: Vaccines Market 130
Figure 24 Glaxosmithkline PLC.: Company Snapshot (2018)
Figure 25 Pfizer, Inc.: Company Snapshot (2018)
Figure 26 Merck & Co., Inc.: Company Snapshot (2018)
Figure 27 Sanofi Pasteur SA: Company Snapshot (2018)
Figure 28 CSL Limited: Company Snapshot (2018)
Figure 29 Emergent Biosolutions, Inc.: Company Snapshot (2018)
Figure 30 Johnson & Johnson: Company Snapshot (2018)
Figure 31 Astrazeneca: Company Snapshot (2018)
Figure 32 Bavarian Nordic: Company Snapshot (2018)
Figure 33 Mitsubishi Tanabe Pharma Corporation: Company Snapshot (2018)
Figure 34 Daiichi Sankyo Company: Company Snapshot (2018)
Figure 35 Panacea Biotec: Company Snapshot (2018)

Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6
5 of 6
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Sanofi Pasteur
  • and Merck & Co. Inc.
  • CSL Limited
  • Emergent BioSolutions Inc.
  • Johnson & Johnson
  • AstraZeneca
  • Serum Institute of India Pvt. Ltd.
  • Bavarian Nordic
  • Mitsubishi Tanabe Pharma Corporation (
  • Daiichi Sankyo
  • Panacea Biotec
  • Biological E
  • Bharat Biotech
  • Sinovac Biotech Ltd.
  • Incepta Vaccine LTD.
  • Valneva SE
  • VBI Vaccines Inc.
  • Bio Farma
Note: Product cover images may vary from those shown
6 of 6

Loading
LOADING...

Adroll
adroll